Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, its diagnosis and prognosis evaluation mainly depends on tissue biopsy and imaging examination. As a part of liquid biopsy, circulating tumor DNA (ctDNA) is a novel noninvasive and real-time tumor-specific biomarker, which can reliably reflect the comprehensive tumor genetic profiles, and it plays an important role in assisting early diagnosis, monitoring the curative effect, prognosis evaluation and prediction of recurrence of DLBCL. This review summarized recent research progress of ctDNA in DLBCL.
题目: 循环肿瘤DNA在弥漫大B细胞淋巴瘤中的临床应用及研究进展.
摘要: 弥漫性大B细胞淋巴瘤（DLBCL）是最常见的非霍奇金淋巴瘤，其诊断和预后评估主要依赖于组织病理活检和影像学检查。作为液体活检的一部分，循环肿瘤DNA是一种新型无创的、实时的肿瘤特异性生物标志物，能够可靠地反映出全面的肿瘤遗传特征，在协助DLBCL早期诊断、疗效监测、预后评估及预测复发等方面均能发挥重要作用。本文对循环肿瘤DNA在DLBCL中的最新研究进展作一综述。.
Keywords: liquid biopsy; circulating tumor DNA; diffuse large B-cell lymphoma.